drugset / Trial / NCT03977103

Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT

NCT03977103

Phase 2 Unknown 80 enrolled University Of Perugia
NaSingle-groupOpen-labelTreatment

Summary

To evaluate if hyper-fractionated TBI or TMLI followed by Treg/Tcon adoptive immunotherapy improve cGvHD/disease free survival after allogeneic HSCT in patients affected by high-risk acute leukemias or other hematologic malignancy where HSCT is indicated.

Timeline

Start
2014-02
Primary completion
2023-02-28
Completion
2023-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Conventional T-Cells Cell therapy 1e+06 cells/kg
Subject Regulatory T cells Cell therapy 2e+06 cells/kg
Background High dose irradiation conditioning + Treg/Tcon Cell therapy 1.07e+07 cells/kg